Professor of Medicine, Division of Hematology Oncology, University of Vermont, Vermont Cancer Center, VT, USA.
Cancer Manag Res. 2012;4:1-8. doi: 10.2147/CMAR.S15551. Epub 2012 Jan 18.
Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory regulator of the T-cell immune response against tumor cells. Ipilimumab is a monoclonal antibody directed against CTLA-4.
This review describes the basic mechanism of ipilimumab and discusses data available to date with regards to its safety and efficacy profile.
Data from clinical trials including abstracts was reviewed using the PubMed Database, as well as the American Society of Clinical Oncology Abstract Database.
CTLA-4 inhibition with a monoclonal antibody is usually well tolerated and has efficacy as a therapeutic agent in a variety of cancers. The classical response interpretation has changed because of the delayed mechanism of action. The toxicities are autoimmune events and guidelines for treatment of these effects are discussed. Therapy with ipilimumab leads to durable responses. The first two Phase III randomized studies showed an improvement of survival at 1, 2, and 3 years. Other studies are currently underway to better understand the optimal treatment administration of ipilimumab in melanoma.
细胞毒性 T 淋巴细胞相关抗原 4（CTLA-4）是一种抑制性调节因子，可调节针对肿瘤细胞的 T 细胞免疫反应。易普利姆玛是一种针对 CTLA-4 的单克隆抗体。
本综述描述了易普利姆玛的基本作用机制，并讨论了迄今为止关于其安全性和疗效的相关数据。
检索 PubMed 数据库和美国临床肿瘤学会摘要数据库中的临床试验数据，包括摘要。
单克隆抗体抑制 CTLA-4 通常具有良好的耐受性，并在多种癌症中具有治疗作用。由于作用机制延迟，经典的反应解释已经改变。这些毒性是自身免疫事件，讨论了治疗这些作用的指南。易普利姆玛治疗可导致持久的反应。前两项 III 期随机研究显示，1、2 和 3 年的生存率有所提高。目前正在进行其他研究，以更好地了解黑色素瘤中易普利姆玛的最佳治疗管理。
